Skip to content

Amgen Inc. v. Sanofi

Petition for certiorari denied on January 7, 2019

Docket No. Op. Below Argument Opinion Vote Author Term
18-127 Fed. Cir. N/A N/A N/A N/A OT 2018

Issue: Whether the standard for determining the adequacy of the "written description of the invention" in a patent must be "in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains . . . to make and use the same," as stated within the Patent Act, 35 U.S.C. § 112(a), or whether court-created standards should control instead.

SCOTUSblog Coverage

DateProceedings and Orders (key to color coding)
05/11/2018Application (17A1262) to extend the time to file a petition for a writ of certiorari from May 24, 2018 to July 23, 2018, submitted to The Chief Justice.
05/14/2018Application (17A1262) granted by The Chief Justice extending the time to file until July 23, 2018.
07/23/2018Petition for a writ of certiorari filed. (Response due August 27, 2018)
08/27/2018Brief amici curiae of Bristol-Myers Squibb Company, Morphosys AG, Bavarian Nordic A/S, and UCB Biopharma SPRL filed.
09/12/2018DISTRIBUTED for Conference of 10/5/2018.
09/18/2018Response Requested. (Due October 18, 2018)
09/20/2018Motion to extend the time to file a response is granted and the time is extended to and including November 19, 2018
09/20/2018Motion to extend the time to file a response from October 18, 2018 to November 17, 2018, submitted to The Clerk.
11/19/2018Brief of respondents Sanofi, et al. in opposition filed.
12/04/2018Reply of petitioners Amgen Inc., et al. filed. (Distributed)
12/05/2018DISTRIBUTED for Conference of 1/4/2019.
01/07/2019Petition DENIED.